ObsEva (OBSV) News Today Add Compare Share Share Headlines Stock AnalysisChartCompetitorsFinancialsSEC FilingsTrends All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street TipRanks The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 February 2022 January 2022 December 2021 Time Period ObsEva (NASDAQ:OBSV) Now Covered by StockNews.comNovember 3 at 2:03 AM | americanbankingnews.comObsEva Announces Delisting from SIX Swiss Exchange and Exemption from Certain Obligations Associated with the Maintenance of ListinApril 3, 2024 | globenewswire.comObsEva Announces Update on Board of DirectorsMarch 19, 2024 | globenewswire.comObsEva Announces Wind-Down of Operations and Notifies SIX that it Will Lack the Resources to Establish Audited IFRS Financial Statements for 2023February 28, 2024 | globenewswire.comObsEva Stock (OTC:OBSEF) Dividends: History, Yield and DatesFebruary 26, 2024 | benzinga.comObsEva SA OBSNNovember 11, 2023 | morningstar.comObsEva SA OBSEFNovember 11, 2023 | morningstar.comObsEva (NASDAQ: OBSV)June 18, 2023 | fool.comObsEva Files Year End 2022 Financial StatementsMarch 31, 2023 | finance.yahoo.comObsEva Announces Progress Towards its Plans to Consolidate Operations in Switzerland: Delisting of OBSV from The Nasdaq Stock Market effective March 23, 2023March 15, 2023 | finance.yahoo.comObsEva Names Fabien De Ladonchamps CEO, Ernest Loumaye Interim ChairmanMarch 13, 2023 | markets.businessinsider.comObsEva Announces Update Towards its Strategic Reorganization to Consolidate Operations in SwitzerlandMarch 13, 2023 | finance.yahoo.comWhy Puma Biotechnology Shares Are Trading Lower By Over 15%? Here Are Other Stocks Moving In Friday's Mid-Day SessionMarch 3, 2023 | benzinga.comWhy Is ObsEva (OBSV) Stock Up 93% Today?March 3, 2023 | investorplace.comWhy ObsEva (OBSV) Stock Is Down 36% TodayFebruary 24, 2023 | investorplace.comObsEva Announces Strategic Reorganization to Consolidate Operations in SwitzerlandFebruary 24, 2023 | finance.yahoo.comObsEva Evidences Compliance with Nasdaq’s Stockholder’s Equity Rule and Announces Moratorium Dismissal Request FilingJanuary 12, 2023 | uk.finance.yahoo.comObsEva Announces Dismissal of Moratorium ProceedingsDecember 19, 2022 | finance.yahoo.comObsEva Evidences Compliance with Nasdaq’s Stockholder’s Equity Rule and Announces Moratorium Dismissal Request FilingDecember 14, 2022 | finance.yahoo.comObsEva SA (OBSV) Reports Q3 Loss, Lags Revenue EstimatesDecember 1, 2022 | finance.yahoo.comObsEva Announces Third Quarter 2022 Financial Results and Provides a Business UpdateDecember 1, 2022 | finance.yahoo.comObsEva Announces Progress on Cost Reduction Initiatives and Stay of Moratorium ProceedingsOctober 27, 2022 | finance.yahoo.comObsEva SA (OBSV)October 16, 2022 | finance.yahoo.comObsEva : China Approves Yuyuan Bioscience's IND Application For Phase 1 Trial Of NolasibanOctober 14, 2022 | markets.businessinsider.comObsEva Announces IND Approval for Yuyuan Bioscience’s Phase 1 Clinical Trial of Nolasiban in China - Yahoo FinanceOctober 13, 2022 | finance.yahoo.comObsEva Says Partner Yuyuan Bioscience Obtained Regulatory Nod for Nolasiban Drug Trial in China - Marketscreener.comOctober 13, 2022 | marketscreener.comObsEva Announces IND Approval for Yuyuan Bioscience's Phase 1 Clinical Trial of Nolasiban in China - ObsE - BenzingaOctober 13, 2022 | benzinga.comObsEva's Chinese Partner Wins Regulatory Nod To Launch Early-stage Trial Of Clinical Pregnancy Drug - Marketscreener.comOctober 13, 2022 | marketscreener.comObsEva Announces IND Approval for Yuyuan Bioscience's Phase - GlobeNewswireOctober 13, 2022 | globenewswire.comObsEva Announces IND Approval for Yuyuan Bioscience’s Phase 1 Clinical Trial of Nolasiban in ChinaOctober 13, 2022 | finance.yahoo.comOBSV.PH - Obseva SA | Stock Price & Latest News | ReutersOctober 6, 2022 | reuters.comObsEva Flat on Restructuring Initiatives - Baystreet.caSeptember 15, 2022 | baystreet.caAfter FDA Regulatory Setback, Penny Stock ObsEva Cuts 70% Of Its StaffSeptember 13, 2022 | finance.yahoo.comObsEva Announces Progress on Restructuring Initiatives - GlobeNewswireSeptember 13, 2022 | globenewswire.comOBSV.O - Obseva SA | Stock Price & Latest News | ReutersSeptember 11, 2022 | reuters.comOBSV.N - Obseva SA | Stock Price & Latest News | ReutersSeptember 10, 2022 | reuters.comThis Women Health Stock Gets Analyst Downgrade On 'Approvability Issues, Restructuring'September 7, 2022 | finance.yahoo.comHot Penny Stocks For Your Buy List in September? 3 to Watch - StreetInsider.comAugust 31, 2022 | streetinsider.comBluebird bio Seeks Back-to-Back Nods, 'Go' or 'No-Go' For Revance's Botox Rival, Amylyx' Twin Hurdles And More: September's Key PDUFA Catalysts Biotech Investors Must Know By Benzinga - Investing.com UKAugust 31, 2022 | uk.investing.comGlobal Female Infertility Drug Pipeline Market Report 2022: Insights about 12 Pipelines Drugs Including Emerging Drugs - OXO-001 (Oxolife) & Nolasiban (ObsEva) - ResearchAndMarkets.com - Business WireAugust 25, 2022 | businesswire.comObsEva stock dips on Nasdaq non-compliance notice - Seeking AlphaAugust 23, 2022 | seekingalpha.comObsEva Receives Nasdaq Non-Compliance Notice - GlobeNewswireAugust 22, 2022 | globenewswire.comObsEva Receives Nasdaq Non-Compliance NoticeAugust 22, 2022 | finance.yahoo.comOBSEVA : INDEX TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS - Form 6-K - Marketscreener.comAugust 19, 2022 | marketscreener.comObsEva: Q2 Earnings Insights - BenzingaAugust 18, 2022 | benzinga.comObsEva Files Second Quarter 2022 Financial Statements - GlobeNewswireAugust 17, 2022 | globenewswire.comObsEva Files Second Quarter 2022 Financial StatementsAugust 17, 2022 | finance.yahoo.comKissei Pharmaceutical : Supplementary Explanatory Materials on Financial Results for the Three Months ended June 30, 2022 - Marketscreener.comAugust 5, 2022 | marketscreener.comAll You Need to Know About ObsEva SA (OBSV) Rating Upgrade to Buy - NasdaqAugust 3, 2022 | nasdaq.comAll You Need to Know About ObsEva SA (OBSV) Rating Upgrade to BuyAugust 3, 2022 | finance.yahoo.com Get ObsEva News Delivered to You Automatically Sign up to receive the latest news and ratings for OBSV and its competitors with MarketBeat's FREE daily newsletter. Email Address This Bull Market Indicator called NVDA at $116 (Ad)Every now and again we find an investment idea so incredible we can’t help but share. And today is one of those rare days… Except, today we won't be giving you insight on any one particular stock… But rather, insight on a revolutionary new stock picking indicator… In fact, within the last year, this indicator has become famous for a multitude of reasons… But one of the biggest was because of the buy signal it issued on October 18th, 2022. In fact, on that very day, it said to buy NVDA at $116.37… Anyone who did would be sitting on a tremendously large return today… But even if you missed the original buy signal from October, this incredible indicator issued 11 other buy signals while Nvidia made its epic run… All you have to do is follow this link here OBSV Media Mentions By Week OBSV Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. OBSV News Sentiment▼0.000.46▲Average Medical News Sentiment OBSV News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. OBSV Articles This Week▼10▲OBSV Articles Average Week Get ObsEva News Delivered to You Automatically Sign up to receive the latest news and ratings for OBSV and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies Acasti Pharma News GlycoMimetics News Dyadic International News Acurx Pharmaceuticals News Enlivex Therapeutics News Lexaria Bioscience News Surrozen News Eyenovia News Lipocine News BioXcel Therapeutics News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:OBSV) was last updated on 11/4/2024 by MarketBeat.com Staff From Our Partners2 sentences that change everything you THOUGHT you knew about tradingIf you're like most people, on Friday morning you'll probably follow your set routine: Wake up... eat breakfas...Investing Daily | SponsoredBill Gates’s Next Big AI Bet: StargateIn February 2016… when almost nobody was talking about artificial intelligence…. I picked Nvidia as one of ...Brownstone Research | SponsoredElection warning coming true… If you missed it, my emergency election broadcast is now available - watch it before it's too late.Porter & Company | Sponsored625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetche...Crypto Swap Profits | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredA Totally New ‘Income Coin’Buckle up… Because this might shatter everything you thought you knew about "income trading." In fact, i...Crypto 101 Media | SponsoredThe centerpiece of Trump’s crypto’s masterplan …Donald Trump wants to be America’s first crypto president. He was the keynote speaker at the recent Bitcoin...Weiss Ratings | SponsoredA new way to play the AI boom (act before November 19)There's a new way to play the $15 trillion AI boom. And it's so simple - you can do it right now with as li...Behind the Markets | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding ObsEva SA Please log in to your account or sign up in order to add this asset to your watchlist. Share ObsEva With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free OBSV Stock Alerts